[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.141.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 21, 1931

THE COMPARATIVE VALUE OF THE ARSPHENAMINES IN THE TREATMENT OF EARLY SYPHILIS

Author Affiliations

NEW YORK

From the Vanderbilt Clinic, Columbia University College of Physicians and Surgeons.

JAMA. 1931;97(21):1523-1530. doi:10.1001/jama.1931.02730210021007
Abstract

Several years ago we were prompted to begin a study of the comparative value of arsphenamine, neoarsphenamine and silver arsphenamine in the treatment of early syphilis, because of the increasing variety of preparations of arsphenamines on the market and the perplexity which we, with most physicians, felt in regard to their relative merits. Adding to this uncertainty were the varying preferences expressed by many of our best syphilologists either as to the drug or as to the plan of treatment.

Irvine,1 in his work at the clinic of the University of Minnesota Medical School, used neoarsphenamine with mercury almost exclusively, and his reports show that the majority of his cases beginning treatment in the early stages and adhering to the prescribed course with this drug became negative and remained so.

In his study of the outpatient clinic and private practice of Dr. Scholtz of Königsberg, Silberstein2 found that

First Page Preview View Large
First page PDF preview
First page PDF preview
×